WebMD

Prolia: A Biannual Injection for Osteoporosis and Bone Loss Management

Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...
AOL

Prolia: Is it covered by Medicare?

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...
Seeking Alpha

NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...
Fierce Healthcare

Amgen’s Prolia Has the Potential to Steal a Prominent Share of the Osteoporosis Market

Majestic Research Study Indicates Physicians Are Enthusiastic about Prolia’s Infrequent Dosing Regimen, but Have Concerns about the High Cost of Therapy However, physicians did express concerns about ...
FiercePharma

Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment

THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...
FierceBiotech

FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture

Given As An Injection Every Six Months, Prolia Reduced Risk Of Fracture At The Spine, Hip And Other Sites THOUSAND OAKS, Calif., June 1, 2010 /PRNewswire via COMTEX/ --Amgen Inc. (Nasdaq: AMGN) today ...
FiercePharma

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment Wi

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, ...
Healio

FDA investigates risk of hypocalcemia for patients on dialysis using Prolia

Please provide your email address to receive an email when new articles are posted on . The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis ...
FierceBiotech

Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alend

New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen ...
Europa Press

mAbxience y Amneal anuncian la aprobación de la FDA de biosimilares de denosumab referidos a Prolia® y XGEVA® (2)

MADRID, 22 de diciembre de 2025 /PRNewswire/ -- mAbxience, grupo participado mayoritariamente por Fresenius Kabi y parcialmente por Insud Pharma, y Amneal Pharmaceuticals, Inc. (Amneal o la Compañía) ...